Please login to the form below
hypoparathyroidism
This page shows the latest hypoparathyroidism news and features for those working in and with pharma, biotech and healthcare.
Shire finally bags EU approval for rare disease drug Natpar
Becomes first licenced treatment for hypoparathyroidism in Europe. Shire is celebrating an EU approval for its hypoparathyroidism treatment Natpar, two years after getting a green light for the drug in the ... hormone therapy for chronic
Latest news
-
J&J gets CHMP backing for broader Darzalex use
ahead for Natpara (parathyroid hormone), a treatment for patients with chronic hypoparathyroidism who cannot be adequately controlled with standard treatment with calcium and vitamin D.
-
Rare disease therapies head the ‘class of 2015’
HDAC inhibitor. Novartis. USA. parathyroid hormone (recombinant). Natpara. hypocalcaemia in hypoparathyroidism.
-
Baxalta agrees to $32bn Shire takeover
drugs such as its HAE therapy Cinryze (C1 esterase inhibitor) and Natpara (recombinant parathyroid hormone) for hypoparathyroidism.
-
Shire deal with Baxalta predicted this week
HAE) therapy DX-2930 - and a $5.2bn purchase of NPS Pharma which gave it control of Natpara (recombinant parathyroid hormone) for hypoparathyroidism.
-
Alexion boosts rare disease portfolio with $8.4bn Synageva buy
hormone) for hypoparathyroidism.
More from news
Approximately 2 fully matching, plus 7 partially matching documents found.
Latest Intelligence
-
Deal Watch October 2018
According to Bloomberg, the products Xiidra eyedrops for dry eye and Natpara for hypoparathyroidism may be considered as a source of funds to reduce the debt Takeda will incur in the
-
Pharma deals during March 2013
84 for adult hypoparathyroidism.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- PMGroup announces launch of new recruitment platform PharmaRole
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- BioNTech reveals plans to spend about €1bn more on research and development this year
- AstraZeneca’s mild combination asthma reliever approved in UK
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- MHRA to introduce new UK clinical trials framework
- Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
- Inizio appoints Stefanie Christmas as global head of DE&I
- The Considered appoints Bam Zahraie as chief experience officer
PMHub
Dovetail
We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
